Oxford Nanopore

Oxford Nanopore's mission is to enable the analysis of any living thing, by anyone, anywhere. The company has successfully transitioned from an academic spin-out to a publicly listed leader, disrupting the genomics industry with its unique long-read, real-time sequencing platform. Its strategy focuses on expanding from research use into regulated clinical diagnostics, biopharma, and applied markets by leveraging the inherent advantages of its scalable technology and end-to-end workflows.

A proprietary nanopore-based sensing platform for real-time, scalable DNA/RNA sequencing that enables direct, long-read analysis of native nucleic acids, including simultaneous detection of nucleotide sequence and base modifications.

Competes directly with Illumina in the broader sequencing market, differentiated by long reads, real-time analysis, and portability. Also competes with Pacific Biosciences in the long-read segment, where ONT offers advantages in ultra-long reads, real-time data, and a wider range of scalable devices. Faces emerging competition from new short-read platforms aiming to disrupt cost structures.